2020, Number 3
<< Back Next >>
Rev Cubana Hematol Inmunol Hemoter 2020; 36 (3)
Congenital dyserythropoietic anemia type I: an updated review about its molecular bases, diagnosis and treatment
Garrote SH
Language: Spanish
References: 27
Page:
PDF size: 375.38 Kb.
ABSTRACT
Introduction:
Congenital dyserythropoietic anemias belong to a group of hereditary disorders characterized by refractory anemia, ineffective erythropoiesis and morphological alterations of erythroblasts. Congenital dyserythropoietic anemia type I is the most frequent; however, it is a rare disease with morphological and molecular characteristics.
Objective:
To analyze the most updated aspects regarding molecular pathogenesis, genetic diagnosis and treatment of congenital dyserythropoietic anemia type I.
Methods:
A review of the literature in English and Spanish was carried out. Search engines such as Google Scholar and Pubmed were used, which allowed access to updated articles on the subject. An analysis and summary of the revised bibliography was carried out.
Information analysis and synthesis:
Congenital dyserythropoietic anemia type I is an autosomal recessive hereditary disease. It is characterized by anemia of variable degree, reticulocytopenia, morphological alterations of the red series in the peripheral lamina, and high number of binucleated erythroblasts connected by internuclear bridges in the bone marrow aspirate. Multiple molecular alterations have been identified, mainly involving the CDAN1 and C15orf41 genes. The proteins encoded by these genes participate in vital processes, such as the cell cycle, DNA repair, and RNA transcription.
Conclusions:
The study of the molecular bases of congenital dyserythropoietic anemia type I has changed the perspective concerning the diagnosis of this disease. Treatment protocols are similar to other hereditary hemolytic anemias, although the use of Interferon-α stands out.
REFERENCES
Greer J, Arber DA, Glader BE, List AF, Means R, Rodgers GM, et al. Wintrobes´s. Clinical Hematology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2018
Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, et al. Williams. Hematology. 9th ed. New York: Mc Graw-Hill; 2016
Heimpel H, Wendt F. Congenital dyserythropoietic anemia with karyorrhexis and multinuclearity of erythroblasts. Helvetica Medica Acta. 1968;34:103-15.
Roy N, Babbs C. The pathogenesis, diagnosis and management of congenital dyserythropoietic anaemia type I. Br J Haematol. 2019 Mar;185(3):436-49.
Brunning R.D, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008.
Goasguen J.E, Bennett J.M, Bain B.J, Brunning R, Vallespi M.T, Tomonaga M, et al. Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid neoplasms: problem areas. Br J Haematol, 2018;182:526-33.
Gambale A, Andolfo I, Russo R, Iolascon A. Diagnosis and management of congenital dyserythropoietic anemias. Expert Rev Haematol. 2016;9:283-96.
Shalev H, Al-Athamen K, Levi I, Levitas A, Tamary H. Morbidity and mortality of adult patients with congenital dyserythropoietic anemia type I. Eur J Haematol. 2017;98:13-8.
Frimmel S, Kniestedt C. Angioid streaks in types I and II congenital dyserythropoietic anaemia (CDA). Klin Monbl Augenheilkd. 2016;233:482-7.
Meznarich JA, Draper L, Christensen RD, Yaish HM, Luem ND, Pysher TJ, et al. Fetal presentation of congenital dyserythropoietic anemia type 1 with novel compound heterozygous CDAN1 mutations. Blood Cells Mol Dis. 2018;71:63-6.
Heimpel H. Congenital dyserythropoietic anemias: epidemiology, clinical significance, and progress in understanding their pathogenesis. Ann Hematol. 2004;83:613-21.
Heimpel H, Schwarz K, Ebnother M, Goede JS, Heydrich D, Kamp T, et al. Congenital dyserythropoietic anemia type I (CDA I): molecular genetics, clinical appearance, and prognosis based on long-term observation. Blood. 2006;107:334-40.
Resnitzky P, Shaft D, Shalev H, Kapelushnik J, Dgany O, Krasnov T, et al. Morphological features of congenital dyserythropoietic anemia type I: the role of electron microscopy in diagnosis. Eur J Haematol. 2017;99:366-71.
Roy NB, Wilson EA, Henderson S, Wray K, Babbs C, Okoli S, et al. A novel 33-Gene targeted resequencing panel provides accurate, clinical-grade diagnosis and improves patient management for rare inherited anaemias. Br J Haematol. 2016;175:318-30.
Russo R, Andolfo I, Manna F, Gambale A, Marra R, Rosato BE, et al. Multi-gene panel testing improves diagnosis and management of patients with hereditary anemias. Am J Hematol. 2018;93:672-82.
Shefer-Averbuch N, Steinberg-Shemer O, Dgany O, Krasnov T, Noy-Lotan S, Yacobovich J, et al. Targeted next generation sequencing for the diagnosis of patients with rare congenital anemias. Eur J Haematol. 2018;101:297-304.
Moir-Meyer G, Cheong PL, Olijnik AA, Brown JM, Knight S, King A, et al. Robust CRISPR/Cas9 genome editing of the HUDEP-2 erythroid precursor line using plasmids and single-stranded oligonucleotide donors. Meth Protocols. 2018;1:28.
Ask K, Jasencakova Z, Menard P, Feng YP, Almouzni G, Groth A. Codanin-1, mutated in the anaemic disease CDAI, regulates Asf1 function in S-phase histone supply. EMBO J. 2012;31:3229.
Laganeckas M, Margelevicius M, Venclovas C. Identification of new homologs of PD-(D/E)XK nucleases by support vector machines trained on data derived from profile-profile alignments. Nucl Acids Res. 2011;39:1187-96.
Jasencakova Z, Groth A. Restoring chromatin after replication: how new and old histone marks come together. Sem Cell Develop Biol. 2010;21:231-7.
Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nature Cell Biol. 2014;16:2-9.
Zhao BB, Mei Y, Schipma MJ, Roth EW, Bleher R, Rappoport JZ, et al. Nuclear condensation during mouse erythropoiesis requires caspase-3-mediated nuclear opening. Developm Cell. 2016;36:498-510.
Davis BA, Allard S, Qureshi A, Porter JB, Pancham S, Win N, et al. Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects. Br J Haematol. 2017;176:179-91.
Lavabre-Bertrand T, Blanc P, Navarro R, Saghroun M, Vannereau H, Braun M, et al. Alpha-Interferon therapy for congenital dyserythropoiesis type I. Br J Haematol. 1995;89:929-32.
Iolascon A, Andolfo I, Barcellini W, Corcione F, Garçon L, De Franceschi L, et al. Recommendations regarding splenectomy in hereditary hemolytic anemias. Haematologica. 2017;102:1304-13.
Voskaridou E, Terpos E. Pathogenesis and management of osteoporosis in thalassemia. Pediatr Endocrinol Rev. 2008;6(1):86-93.
Roy NB, Pavord S. Management of other inherited red cell disorders in pregnancy. In: Pavord S, Hunt B, eds. The Obstetric Hematology Maual. Cambridge: Cambridge University Press; 2018. p. 93-103.